The data presented here may serve as a basis for clinical studies that help to assess a prognostic or predictive value of the analytical procedure in particular in respect to the new treatment options like T-Dxd which was approved from FDA for treatment of advanced HER2-positive gastric cancer in January 2021. This evidence concerns the gene ERBB2 and gastric cancer.